• Oct 23, 2026

  $21.19-3.37%

  Comparable pharmaceutical preparations companies fell 1.18% on average, with 4 of 6 lower [1]. The company's 3.37% decline was larger than the cohort's average move [1]. Volume ran at 0.6x its trailing 20-session average, and the session range was 21.13 to 21.97 [2].

  • 1Peer group
  • 2Market data

• Oct 22, 2026

  $21.93-0.36%

  Comparable Pharmaceutical Preparations companies moved -1.08% on average, with 3 of 6 falling and 2 rising [1]. GPCR slipped 0.36%, a much smaller decline than the cohort average. Volume was 0.5x its trailing 20-session average [2].

  • 1Peer group
  • 2Market data

• Oct 21, 2026

  $22.01-3.80%

  GPCR fell 3.80%, a larger drop than the -0.76% average move of comparable Pharmaceutical Preparations companies, of which 5 of 6 fell [1]. The decline was therefore only partly shared by the cohort. Volume was 0.5x its trailing 20-session average, and the session ranged from 21.77 to 23.32 [2].

  • 1Peer group
  • 2Market data

• Oct 20, 2026

  $22.88+3.95%

  The shares rose 3.95% alongside a sector-wide gain. Comparable pharmaceutical companies rose 3.81% on average, and all 6 of them advanced [1].

  • 1Peer group

• Oct 19, 2026

  $22.01+4.41%

  Comparable pharmaceutical preparations companies rose 0.97% on average, with three of six falling and three rising [2]. The company's 4.41% gain was well ahead of that cohort average, so the move was not shared to the same degree [2]. Globenewswire carried an announcement of multiple upcoming presentations at ObesityWeek 2026 [1].

  • 1Globenewswire
  • 2Peer group

• Oct 16, 2026

  $21.08-5.00%

  Comparable pharmaceutical preparations companies fell 4.41% on average on the day, with 4 of 6 falling and 1 rising [1]. The company's 5.00% decline came alongside that sector-wide weakness rather than apart from it [1].

  • 1Peer group

• Oct 15, 2026

  $22.19+1.42%

  Comparable Pharmaceutical Preparations companies rose 3.36% on average, with all 6 higher [1]. GPCR's 1.42% gain came alongside that sector advance but was smaller than the cohort average [1].

  • 1Peer group

Closing prices for GPCR. Summaries describe past sessions only and are not advice, a forecast or a recommendation.

Headlines are published by third parties and linked as reported. Amaltash does not endorse or verify them.